Compare · EW vs MDT
EW vs MDT
Side-by-side comparison of Edwards Lifesciences Corporation (EW) and Medtronic plc. (MDT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. EW focuses on Industrial Specialties, while MDT focuses on Biotechnology: Electromedical & Electrotherapeutic Apparatus.
- MDT is the larger of the two at $123.49B, about 2.3x EW ($53.03B).
- MDT has been more active in the news (18 items in the past 4 weeks vs 3 for EW).
- Both have 25 recent analyst ratings on file.
- Company
- Edwards Lifesciences Corporation
- Medtronic plc.
- Price
- -
- -
- Market cap
- $53.03B
- $123.49B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Industrial Specialties
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 3
- 18
- Recent ratings
- 25
- 25
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Latest EW
- CLASP II TR Trial Demonstrates Superior Clinical, Quality-of-Life Benefits With Edwards PASCAL System
- Progress Trial Demonstrates Edwards TAVR Is Superior to Clinical Surveillance for Moderate AS Patients With At-Risk Features
- FDA Approval of Edwards Lifesciences’ PASCAL Precision System Opens New Treatment Pathway for Patients With Tricuspid Valve Disease
- CVP, TAVR Lippis Daniel J. sold $53,017 worth of shares (619 units at $85.65) as part of a pre-agreed trading plan (SEC Form 4)
- Barclays initiated coverage on Edwards Lifesciences with a new price target
- Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026
- Edwards Lifesciences to Host Investor Event in Conjunction With TCT
- Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients
- SVP, Corporate Controller Dahl Andrew M. covered exercise/tax liability with 253 shares, decreasing direct ownership by 2% to 14,615 units (SEC Form 4) to satisfy withholding tax
- CVP, JAPAC Markowitz Wayne covered exercise/tax liability with 923 shares, decreasing direct ownership by 5% to 19,371 units (SEC Form 4) to satisfy tax liability
Latest MDT
- Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SAB
- Medtronic announces positive results from real-world registries for the Sphere-9™ catheter and PulseSelect™ PFA System at APHRS 2026
- SEC Form 4 filed by Medtronic plc.
- SEC Form 11-K filed by Medtronic plc.
- SEC Form 11-K filed by Medtronic plc.
- SEC Form 8-K filed by Medtronic plc.
- EVP, Pres MedSurg and Americas Marinaro Michael sold $1,000,320 worth of Ordinary Shares (10,420 units at $96.00) as part of a pre-agreed trading plan (SEC Form 4)
- Chairman and CEO Martha Geoffrey sold $4,750,000 worth of Ordinary Shares (50,000 units at $95.00) as part of a pre-agreed trading plan (SEC Form 4)
- Medtronic Named to TIME Best Inventions of 2026 List for Stealth AXiS™ surgical system and Corsano™* multi-parameter wearable
- MiniMed Completes Separation from Medtronic